NASDAQ:DRRX - DURECT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.60
  • Forecasted Upside: 302.44 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$1.64
▼ -0.07 (-4.09%)
1 month | 3 months | 12 months
Get New DURECT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.60
▲ +302.44% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for DURECT in the last 3 months. The average price target is $6.60, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 302.44% upside from the last price of $1.64.
Buy
The current consensus among 6 investment analysts is to buy stock in DURECT. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/3/2021Chardan CapitalBoost Price TargetBuy$7.00 ➝ $8.00High
i
Rating by M. Morabito at Chardan Capital
11/26/2020Chardan CapitalReiterated RatingBuy$7.00Low
i
Rating by M. Morabito at Chardan Capital
10/30/2020Chardan CapitalInitiated CoverageBuy$7.00Medium
i
Rating by M. Morabito at Chardan Capital
10/12/2020Roth CapitalInitiated CoverageBuy$7.00Low
i
Rating by E. Piros at Roth Capital
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by K. Kluska at Cantor Fitzgerald
7/30/2020OppenheimerInitiated CoverageOutperform$7.00High
i
6/29/2020B. RileyReiterated RatingBuy$5.00High
i
Rating by Mayank Mamtani at B. Riley
5/27/2020HC WainwrightBoost Price TargetBuy$5.50 ➝ $6.00High
i
5/26/2020B. RileyReiterated RatingBuy$5.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/12/2020B. RileyReiterated RatingBuy$5.00High
i
Rating by Mayank Mamtani at B. Riley
5/12/2020HC WainwrightReiterated RatingBuy$5.50Medium
i
3/4/2020B. RileyReiterated RatingBuy$5.00High
i
Rating by Mayank Mamtani at B. Riley
1/31/2020B. RileyInitiated CoverageBuy$5.00Medium
i
Rating by M. Mamtani at B. Riley
1/22/2020Craig HallumInitiated CoverageBuyMedium
i
1/3/2020HC WainwrightReiterated RatingBuy$5.50High
i
Rating by Ed Arce at HC Wainwright
11/18/2019Cantor FitzgeraldInitiated CoverageBuy$5.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by E. Merle at Cantor Fitzgerald
9/18/2019HC WainwrightSet Price TargetBuy$3.50Low
i
Rating by Ed Arce at HC Wainwright
9/18/2019Stifel NicolausBoost Price TargetHold$1.50 ➝ $2.10Low
i
9/10/2019HC WainwrightReiterated RatingBuy$3.50High
i
Rating by Ed Arce at HC Wainwright
9/6/2019Cantor FitzgeraldInitiated CoverageOverweight$5.00High
i
Rating by E. Piros at Cantor Fitzgerald
7/19/2019HC WainwrightSet Price TargetBuy$4.00Low
i
Rating by Ed Arce at HC Wainwright
5/9/2019HC WainwrightReiterated RatingBuy$3.50Medium
i
Rating by E. Arce at HC Wainwright
4/18/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by E. Arce at HC Wainwright
1/7/2019HC WainwrightReiterated RatingBuy$3.00High
i
7/31/2018HC WainwrightReiterated RatingBuy$3.00High
i
Rating by E. Arce at HC Wainwright
3/6/2018HC WainwrightUpgradeNeutral ➝ Buy$1.50 ➝ $3.50High
i
Rating by E. Arce at HC Wainwright
11/2/2017HC WainwrightReiterated RatingHoldN/A
i
Rating by E. Arce at HC Wainwright
10/20/2017LaidlawLower Price TargetBuy ➝ Buy$3.00 ➝ $2.00N/A
i
10/20/2017HC WainwrightDowngradeBuy ➝ Neutral$3.00N/A
i
Rating by E. Arce at HC Wainwright
10/20/2017Stifel NicolausDowngradeBuy ➝ HoldN/A
i
7/12/2017Stifel NicolausUpgradeHold ➝ Buy$1.25 ➝ $3.00High
i
6/25/2017HC WainwrightReiterated RatingBuy$3.00Low
i
Rating by E. Arce at HC Wainwright
5/22/2017HC WainwrightReiterated RatingBuy$3.00Medium
i
Rating by E. Arce at HC Wainwright
3/16/2017HC WainwrightReiterated RatingBuy$3.00Medium
i
Rating by E. Arce at HC Wainwright
2/28/2017HC WainwrightReiterated RatingBuy ➝ Buy$3.00N/A
i
Rating by E. Arce at HC Wainwright
9/27/2016Rodman & RenshawReiterated RatingBuy$4.00 ➝ $3.50N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
8/3/2016Rodman & RenshawReiterated RatingBuy$4.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
7/6/2016Rodman & RenshawReiterated RatingBuy$4.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
5/13/2016Rodman & RenshawReiterated RatingBuy$4.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
4/25/2016Rodman & RenshawInitiated CoverageBuy$4.00N/A
i
(Data available from 4/19/2016 forward)
DURECT logo
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Read More

Today's Range

Now: $1.64
$1.61
$1.73

50 Day Range

MA: $2.06
$1.74
$2.37

52 Week Range

Now: $1.64
$1.52
$2.96

Volume

836,637 shs

Average Volume

2,070,754 shs

Market Capitalization

$372.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of DURECT?

The following equities research analysts have issued reports on DURECT in the last twelve months: B. Riley, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Oppenheimer Holdings Inc., Roth Capital, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for DRRX.

What is the current price target for DURECT?

5 Wall Street analysts have set twelve-month price targets for DURECT in the last year. Their average twelve-month price target is $6.60, suggesting a possible upside of 302.4%. Chardan Capital has the highest price target set, predicting DRRX will reach $8.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $5.00 for DURECT in the next year.
View the latest price targets for DRRX.

What is the current consensus analyst rating for DURECT?

DURECT currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DRRX will outperform the market and that investors should add to their positions of DURECT.
View the latest ratings for DRRX.

What other companies compete with DURECT?

How do I contact DURECT's investor relations team?

DURECT's physical mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company's listed phone number is 408-777-1417 and its investor relations email address is [email protected] The official website for DURECT is www.durect.com.